Key clinical point: Subcutaneous hepatitis A vaccination is as immunogenic, but appeared safer than intramuscular injections for bleeding disorder patients.

Major finding: A total of 38 patients assessed after first vaccine dose showed seroconversion rates of 83.3% and 90.0% for the subcutaneous versus the intramuscular group, respectively.

Study details: A comparison of hepatitis A vaccination administered subcutaneously or intramuscularly in 78 children and adults with hemophilia and other bleeding disorders.

Disclosures: The authors declared that they had no disclosures.